BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 32522824)

  • 21. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
    Shafran JS; Andrieu GP; Györffy B; Denis GV
    Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer.
    Lu D; Song Y; Yu Y; Wang D; Liu B; Chen L; Li X; Li Y; Cheng L; Lv F; Zhang P; Xing Y
    Cell Death Dis; 2021 Aug; 12(8):787. PubMed ID: 34381019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer.
    Lee KH; Hong S; Kang M; Jeong CW; Ku JH; Kim HH; Kwak C
    Int J Cancer; 2018 Dec; 143(11):2849-2861. PubMed ID: 30183076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of ubiquitin ligases in castration-resistant prostate cancer.
    Qi J; Fan L; Hussain A
    Curr Opin Oncol; 2015 May; 27(3):172-6. PubMed ID: 25811345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation.
    Duan L; Chen Z; Lu J; Liang Y; Wang M; Roggero CM; Zhang QJ; Gao J; Fang Y; Cao J; Lu J; Zhao H; Dang A; Pong RC; Hernandez E; Chang CM; Hoang DT; Ahn JM; Xiao G; Wang RT; Yu KJ; Kapur P; Rizo J; Hsieh JT; Luo J; Liu ZP
    Nucleic Acids Res; 2019 Dec; 47(22):11623-11636. PubMed ID: 31647098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.
    Choo N; Keerthikumar S; Ramm S; Ashikari D; Teng L; Niranjan B; Hedwards S; Porter LH; Goode DL; Simpson KJ; Taylor RA; Risbridger GP; Lawrence MG
    J Pathol; 2024 Jun; 263(2):242-256. PubMed ID: 38578195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/β-catenin signaling.
    Peng K; Su G; Ji J; Yang X; Miao M; Mo P; Li M; Xu J; Li W; Yu C
    J Biol Chem; 2018 Jul; 293(27):10606-10619. PubMed ID: 29802196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
    Han D; Gao S; Valencia K; Owiredu J; Han W; de Waal E; Macoska JA; Cai C
    Oncotarget; 2017 Jan; 8(4):6796-6808. PubMed ID: 28036278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
    Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
    Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone Demethylase JMJD1A Promotes Tumor Progression via Activating Snail in Prostate Cancer.
    Tang DE; Dai Y; Xu SH
    Mol Cancer Res; 2020 May; 18(5):698-708. PubMed ID: 32019811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
    Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B
    Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNF8 up-regulates AR/ARV7 action to contribute to advanced prostate cancer progression.
    Zhou T; Wang S; Song X; Liu W; Dong F; Huo Y; Zou R; Wang C; Zhang S; Liu W; Sun G; Lin L; Zeng K; Dong X; Guo Q; Yi F; Wang Z; Li X; Jiang B; Cao L; Zhao Y
    Cell Death Dis; 2022 Apr; 13(4):352. PubMed ID: 35428760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.
    Ji D; Shang G; Wei E; Jia Y; Wang C; Zhang Q; Zeng L
    Oncogene; 2022 Jun; 41(23):3251-3262. PubMed ID: 35513563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
    Shah K; Gagliano T; Garland L; O'Hanlon T; Bortolotti D; Gentili V; Rizzo R; Giamas G; Dean M
    Oncogene; 2020 Sep; 39(39):6172-6189. PubMed ID: 32820253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.
    Zadra G; Ribeiro CF; Chetta P; Ho Y; Cacciatore S; Gao X; Syamala S; Bango C; Photopoulos C; Huang Y; Tyekucheva S; Bastos DC; Tchaicha J; Lawney B; Uo T; D'Anello L; Csibi A; Kalekar R; Larimer B; Ellis L; Butler LM; Morrissey C; McGovern K; Palombella VJ; Kutok JL; Mahmood U; Bosari S; Adams J; Peluso S; Dehm SM; Plymate SR; Loda M
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):631-640. PubMed ID: 30578319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.
    Duan L; Chen YA; Liang Y; Chen Z; Lu J; Fang Y; Cao J; Lu J; Zhao H; Pong RC; Hernandez E; Kapur P; Tran TAT; Smith T; Martinez ED; Ahn JM; Hsieh JT; Luo JH; Liu ZP
    Biomed Pharmacother; 2023 Feb; 158():114077. PubMed ID: 36495660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
    Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
    Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer.
    Zhang A; Zhao JC; Kim J; Fong KW; Yang YA; Chakravarti D; Mo YY; Yu J
    Cell Rep; 2015 Oct; 13(1):209-221. PubMed ID: 26411689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.